Dual Antiplatelet Therapy following Percutaneous Coronary Intervention

This report presents a summary of a health technology assessment (HTA) report published by the Canadian Agency for Drugs and Technologies in Health that evaluated the evidence pertaining to the comparative clinical efficacy and safety of six to 12 months dual antiplatelet therapy (DAPT) versus extended DAPT (>12 months), following percutaneous coronary intervention with stent insertion in coronary artery disease patients and various subpopulations.

Last modification 13.11.2020

Top of page

Contact

Federal Office of Public Health FOPH
Health insurance benefits Division
Health Technology Assessment Section
Schwarzenburgstrasse 157
3003 Bern
Switzerland
Tel. +41 58 469 17 33
E-mail

Print contact

https://www.bag.admin.ch/content/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/dualeantithrombozytaeretherapie.html